bioRxivCancer BiologyPreprint
Radiotherapy drives lung metastasis in PDAC via a RhoGTPasesignaling shift towards MRCK-dependency
Kathy McLayiD, Mathias TessoniD, Louise R. DuttoniD, Yihong SuniD, Josette M Misquitta, Katrina H. StevensoniD, Ryan CorbyniD, Sérgio LillaiD, Lynn McGarryiD, N Maka, R ShawiD, Crispin J. MilleriD, LM CarliniD, AJ Chalmers, Michael F. OlsoniD, JP Morton, JL BirchiD
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with an extremely poor prognosis, partly owing to its highly metastatic nature. Although radiotherapy is an effective and potentially curative treatment modality, research over the last few decades has indicated that it may induce a more metastatic phenotype in surviving cancer cells. We demonstrate for the first time that clinically relevant doses of image-guided targeted radiotherapy induce metastasis in a genetically engineered KPC mouse model of PDAC. Furthermore, this induction is largely driven by an organotropic switch towards lung metastasis. Using an in vitro RNAi screening approach, we identified a key role for myotonic dystrophy-related Cdc42-binding kinase (MRCK) in driving this response. MRCK activity was spatially upregulated at the plasma membrane in response to radiotherapy in PDAC cell lines as well as at the invasive margins of PDAC tumors. This upregulation of activity was maintained in metastases, suggesting an important role for MRCK in not only triggering local invasion in response to radiotherapy but also promoting distant metastases. Importantly, inhibition of MRCK with a small-molecule inhibitor (BDP9066) specifically opposed radiation-driven MRCK upregulation and pro-metastatic response.
- organism: mouse
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- RhoV Promotes Proliferation, Migration, and MAPK Activation in Pancreatic Ductal Adenocarcinoma
Shang Wu, Jia Feng, … Shuai Lü·American Journal Of PathologyPeer-reviewed·Feb 26, 2026
- Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis
S. F. Bannoura, A. Aboukameel, … A. S. Azmi·bioRxiv·Dec 18, 2023
- Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment
Tianyu Wang, Linghua Wang, … Albert C. Koong·bioRxiv·Jul 13, 2026
- Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDAC
Claire M. Pfeffer, Sydney J. Clifford, … Brittany L. Allen-Petersen·bioRxiv·Jul 18, 2025
- Adaptation to ARF6-depletion in KRAS-driven PDAC is abolished by targeting TLR2
- Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner
K. K. Mahadevan, K. McAndrews, … R. Kalluri·bioRxiv·Feb 15, 2023